You have accessJournal of UrologyCME1 Apr 2023PD35-10 IMPACT ON POSTOPERATIVE ORAL MORBIDITY AND MID-TERM EFFICACY OF ANTERIOR URETHROPLASTY USING AN AUTOLOGOUS TISSUE-ENGINEERED ORAL MUCOSA GRAFT (MUKOCELL®) VERSUS NATIVE ORAL MUCOSA GRAFT Leonidas Karapanos, Vincent Knorr, Luisa Halbe, Maximilian Schmautz, Bobirjon Ergashev, Andijan Uzbekistan, and Axel Heidenreich Leonidas KarapanosLeonidas Karapanos More articles by this author , Vincent KnorrVincent Knorr More articles by this author , Luisa HalbeLuisa Halbe More articles by this author , Maximilian SchmautzMaximilian Schmautz More articles by this author , Bobirjon ErgashevBobirjon Ergashev More articles by this author , Andijan UzbekistanAndijan Uzbekistan More articles by this author , and Axel HeidenreichAxel Heidenreich More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003333.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The aim of our study was to compare the outcomes and complication rates of augmentation urethroplasty using autologous tissue-engineered oral mucosa graft (TEOMG) versus native oral mucosa graft (NOMG), aiming to determine the appropriate indications for TEOMG use (MukoCell®) in urethral surgery. METHODS: We conducted a single-institution retrospective study on 153 patients undergoing augmentation urethroplasty for anterior urethral strictures >2 cm in length from January 2016 to July 2020. TEOMG was used in 77 and NOMG in 76 patients, respectively. The success rate, complications including postinterventional oral morbidity, and risk factors of recurrence between both groups were analyzed. Postoperative follow-up (FU) examinations were performed at 6 and 12 months and subsequently yearly. A decrease of Qmax value <15 ml/s or further instrumentation were considered a failure. RESULTS: Overall, TEOMG and NOMG had comparable success rates (68.8% vs. 78.9%, p=0.155) after a median follow-up of 52 (IQR 45-60) months for TEOMG and 53.5 (IQR 43-58) months for NOMG. Subgroup analysis revealed similar success rates according to surgical technique, stricture localization, and length. Only following repetitive urethral dilatations, TEOMG achieved significantly lower success rates (31.3% vs. 81.3%, p=0.003). Surgical time could be reduced through TEOMG use with a median of 104 (IQR 86-130) vs. 182 (IQR 154-214) minutes in the NOMG group (p<0.001). Both early and late oral morbidity were diminished through the biopsy taken for TEOMG manufacture, compared to NOMG harvesting. Twelve months postoperatively, the prevalence of sensory disorders still showed a significant disparity between groups, with occurrence only in the NOMG group (0 vs. 9.2%, p=0.006). CONCLUSIONS: The success rate of augmentation urethroplasty using TEOMG was statistically comparable to NOMG at a mid-term FU. Surgical time was significantly shortened since no intraoperative mucosa harvesting was required, and oral complications were diminished through the preoperative biopsy for MukoCell® manufacture. Source of Funding: No funding © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e978 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Leonidas Karapanos More articles by this author Vincent Knorr More articles by this author Luisa Halbe More articles by this author Maximilian Schmautz More articles by this author Bobirjon Ergashev More articles by this author Andijan Uzbekistan More articles by this author Axel Heidenreich More articles by this author Expand All Advertisement PDF downloadLoading ...
Read full abstract